CVRx, Inc. (CVRX) shareholders
Close on Nov 17, 2026Market cap $16.28MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Johnson & Johnson Joint filing with Johnson & Johnson Innovation - JJDC, Inc. (15.40%) | 4,024,861 | 15.40% | 13G (passive) amendment | Dec 31, 2025 |
| NEA Partners 10, Limited Partnership Joint filing with New Enterprise Associates 10, Limited Partnership (7.80%), Anthony A. Florence, Jr. (7.80%) and 2 more | 2,026,083 | 7.80% | 13D (active) amendment | Feb 18, 2025 |
| Kirk Nielsen Joint filing with Vensana Capital I GP, LLC (7.10%), Vensana Capital I, L.P. (7.10%) and 1 more | 1,760,734 | 7.20% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CVRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Johnson & Johnson | 4,024,861 | 15.11% | $20.69M | – | 2.59% |
| NEA Management Company, LLC | 1,954,440 | 7.34% | $10.05M | −71,643 | 0.63% |
| BlackRock, Inc. | 1,245,459 | 4.67% | $6.40M | +218,900 | 0.00% |
| Royal Bank of Canada | 1,233,212 | 4.63% | $6.34M | +526,262 | 0.00% |
| GSK plc | 1,007,583 | 3.78% | $5.18M | – | 0.86% |
| Vanguard Capital Management LLC | 910,576 | 3.42% | $4.68M | −734 | 0.00% |
| Silvercrest Asset Management Group LLC | 878,109 | 3.30% | $4.51M | +306,088 | 0.03% |
| Geode Capital Management, LLC | 440,786 | 1.65% | $2.27M | +13,714 | 0.00% |
| PFM Health Sciences, LP | 369,572 | 1.39% | $1.90M | New | 0.16% |
| State Street Corp | 366,352 | 1.38% | $1.88M | +15,804 | 0.00% |
| Renaissance Technologies LLC | 230,000 | 0.86% | $1.18M | +210,700 | 0.00% |
| UBS Group AG | 224,233 | 0.84% | $1.15M | +120,423 | 0.00% |
| Tudor Investment Corp Et Al | 205,684 | 0.77% | $1.06M | +8,344 | 0.00% |
| Goldman Sachs Group Inc | 149,509 | 0.56% | $768.48K | −51,502 | 0.00% |
| Morgan Stanley | 144,977 | 0.54% | $745.18K | +5,613 | 0.00% |
| Kestra Advisory Services, LLC | 132,400 | 0.50% | $680.54K | +84,500 | 0.00% |
| Two Sigma Investments, LP | 132,398 | 0.50% | $680.53K | +18,231 | 0.00% |
| Vanguard Fiduciary Trust Co | 128,955 | 0.48% | $662.83K | +1,194 | 0.00% |
| Dimensional Fund Advisors LP | 127,971 | 0.48% | $659.87K | +75,330 | 0.00% |
| Northern Trust Corp | 124,767 | 0.47% | $641.30K | −25,356 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 88 | 15M | 57.4% | 9 / 35 | 28 / 18 | 2M | 2M |
| Q1 2026 | 99 | 15M | 55.1% | 23 / 34 | 21 / 15 | 3M | 2M |
| Q4 2025 | 92 | 15M | 57.2% | 9 / 29 | 33 / 8 | 2M | 1M |
| Q3 2025 | 93 | 14M | 52.7% | 14 / 34 | 26 / 13 | 1M | 1M |
| Q2 2025 | 92 | 15M | 54.7% | 20 / 34 | 20 / 24 | 2M | 3M |
| Q1 2025 | 96 | 16M | 60.3% | 17 / 35 | 24 / 13 | 2M | 1M |
| Q4 2024 | 93 | 15M | 56.9% | 19 / 26 | 30 / 12 | 2M | 1M |
| Q3 2024 | 86 | 14M | 53.5% | 21 / 36 | 16 / 7 | 3M | 1M |
| Q2 2024 | 73 | 13M | 49.5% | 13 / 36 | 17 / 28 | 2M | 3M |
| Q1 2024 | 88 | 14M | 54.4% | 21 / 32 | 21 / 16 | 3M | 1M |
| Q4 2023 | 83 | 13M | 48.4% | 23 / 23 | 26 / 4 | 2M | 1M |
| Q3 2023 | 64 | 12M | 46.6% | 9 / 20 | 22 / 11 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
95 funds held CVRX in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CVRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 684,121 | 2.57% | $3.52M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 371,607 | 1.39% | $1.91M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 204,533 | 0.77% | $1.05M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 165,915 | 0.62% | $858.61K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 156,004 | 0.59% | $801.86K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 96,327 | 0.36% | $537.50K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 81,934 | 0.31% | $457.19K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 51,597 | 0.19% | $265.21K | 0.02% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 36,500 | 0.14% | $187.61K | 0.13% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 35,398 | 0.13% | $183.18K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 34,330 | 0.13% | $191.56K | 0.00% | May 31, 2026 |
| U.S. Small Cap Equity Fund | 32,926 | 0.12% | $170.39K | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 28,363 | 0.11% | $146.78K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 27,837 | 0.10% | $155.33K | 0.00% | May 31, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 27,822 | 0.10% | $143.98K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kevin Hykes | PRES & CEO, Director | 284,237 | 1.07% | Mar 3, 2026 |
| John Landry | Chief Financial Officer | 41,433 | 0.16% | Nov 12, 2026 |
| Brent Binkowski | CHIEF OPERATING OFFICER | 56,514 | 0.21% | Aug 13, 2026 |
| Philip B. Adamson | Chief Medical Officer | 61,578 | 0.23% | Mar 16, 2026 |
| Gregory Morrison | CHIEF HUMAN RESOURCES OFFICER | 34,000 | 0.13% | Mar 4, 2026 |
| Jared Oasheim | CHIEF FINANCIAL OFFICER | 96,703 | 0.36% | Mar 3, 2026 |
| Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 60,551 | 0.23% | Mar 3, 2026 |
| Robert Allen John | Chief Revenue Officer | 86,036 | 0.32% | Mar 3, 2026 |
| Hill, Mitch C. | Director | 8,720 | 0.03% | Jun 3, 2026 |
| Martha Shadan | Director | 8,720 | 0.03% | Jun 3, 2026 |
| Mudit K. Jain | Director | 994,553 | 3.73% | Jun 3, 2026 |
| Joseph P. Slattery | Director | 39,365 | 0.15% | Jun 3, 2026 |
| Michael D. Dale | Director | 29,005 | 0.11% | Jun 3, 2026 |
| Kirk G. Nielsen | Director | 1,918,854 | 7.20% | Jun 3, 2026 |
| Kevin J. Ballinger | Director | 8,720 | 0.03% | Jun 3, 2026 |
| Johnson & Johnson Innovation - JJDC, Inc. | 10% owner | 4,024,861 | 15.11% | Jan 8, 2026 |
| & Johnson Johnson | 10% owner | 4,040,861 | 15.17% | Jan 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Landry Chief Financial Officer | Nov 9, 2026 | Award | +41,433 | – | – | 41,433 |
| Brent Binkowski CHIEF OPERATING OFFICER | Aug 13, 2026 | Buy | +26,223 | $2.91 | $76.31K | 56,514 |
| Brent Binkowski CHIEF OPERATING OFFICER | Aug 12, 2026 | Sale(10b5-1 plan) | −1,309 | $2.55 | $3.34K | 30,291 |
| Mudit K. Jain Director | Jun 1, 2026 | Award | +8,720 | – | – | 14,370 |
| Martha Shadan Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Kirk G. Nielsen Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Kevin J. Ballinger Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Hill, Mitch C. Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Michael D. Dale Director | Jun 1, 2026 | Award | +29,005 | – | – | 29,005 |
| Joseph P. Slattery Director | Jun 1, 2026 | Award | +8,720 | – | – | 39,365 |
| Philip B. Adamson Chief Medical Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,262 | $7.90 | $9.97K | 61,578 |
| Gregory Morrison CHIEF HUMAN RESOURCES OFFICER | Mar 2, 2026 | Award | +34,000 | – | – | 34,000 |
| Kevin Hykes PRES & CEO, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −7,763 | $7.90 | $61.33K | 284,237 |
| Jared Oasheim CHIEF FINANCIAL OFFICER | Mar 2, 2026 | Sale(10b5-1 plan) | −1,744 | $7.90 | $13.78K | 96,703 |
| Robert Allen John Chief Revenue Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −3,964 | $7.90 | $31.32K | 86,036 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Mar 2, 2026 | Sale(10b5-1 plan) | −1,284 | $7.90 | $10.14K | 60,551 |
| Philip B. Adamson Chief Medical Officer | Feb 27, 2026 | Award | +41,000 | – | – | 62,840 |
| Brent Binkowski CHIEF OPERATING OFFICER | Feb 27, 2026 | Award | +15,000 | – | – | 31,600 |
| Kevin Hykes PRES & CEO, Director | Feb 27, 2026 | Award | +159,000 | – | – | 292,000 |
| Jared Oasheim CHIEF FINANCIAL OFFICER | Feb 27, 2026 | Award | +61,000 | – | – | 98,447 |
| Robert Allen John Chief Revenue Officer | Feb 27, 2026 | Award | +35,000 | – | – | 90,000 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Feb 27, 2026 | Award | +45,000 | – | – | 61,835 |
| Mudit K. Jain Director | Feb 20, 2026 | Buy | +46,800 | $6.36 | $297.65K | 980,183 |
| Mudit K. Jain Director | Feb 18, 2026 | Buy | +600 | $4.64 | $2.78K | 5,650 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 26, 2025 | Sale | −6,337 | $10.03 | $63.56K | 4,024,861 |
| & Johnson Johnson 10% owner | Nov 26, 2025 | Sale | −6,337 | $10.03 | $63.56K | 4,040,861 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 25, 2025 | Sale | −16,000 | $10.03 | $160.48K | 4,031,198 |
| & Johnson Johnson 10% owner | Nov 24, 2025 | Sale | −2,200 | $10.06 | $22.13K | 4,047,198 |
| & Johnson Johnson 10% owner | Nov 21, 2025 | Sale | −500 | $10.00 | $5.00K | 4,049,398 |
| & Johnson Johnson 10% owner | Nov 12, 2025 | Sale | −1,000 | $10.00 | $10.00K | 4,049,898 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 7, 2025 | Sale | −200 | $10.00 | $2.00K | 4,050,898 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 6, 2025 | Sale | −52,332 | $10.21 | $534.31K | 4,051,098 |
| Brent Binkowski CHIEF OPERATING OFFICER | Aug 11, 2025 | Award | +16,600 | – | – | 16,600 |
| Kirk G. Nielsen Director | May 15, 2025 | Buy | +10,966 | $5.45 | $59.76K | 1,910,134 |
| Kirk G. Nielsen Director | May 14, 2025 | Buy | +61,200 | $5.23 | $320.08K | 1,899,168 |
| Kirk G. Nielsen Director | May 13, 2025 | Buy | +101,413 | $5.29 | $536.47K | 1,837,968 |
| Mudit K. Jain Director | May 13, 2025 | Buy | +150 | $5.26 | $789 | 5,050 |
| Kirk G. Nielsen Director | May 12, 2025 | Buy | +25,200 | $4.79 | $120.71K | 1,736,555 |
| Mudit K. Jain Director | May 12, 2025 | Buy | +1,500 | $4.66 | $6.99K | 4,900 |
| Kevin Hykes PRES & CEO, Director | May 12, 2025 | Buy | +5,000 | $4.84 | $24.20K | 133,000 |
| Jared Oasheim CHIEF FINANCIAL OFFICER | Feb 28, 2025 | Award | +22,000 | – | – | 37,447 |
| Robert Allen John Chief Revenue Officer | Feb 28, 2025 | Award | +55,000 | – | – | 55,000 |
| Kevin Hykes PRES & CEO, Director | Feb 28, 2025 | Award | +98,000 | – | – | 128,000 |
| Philip B. Adamson Chief Medical Officer | Feb 28, 2025 | Award | +20,000 | – | – | 20,000 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Feb 28, 2025 | Award | +16,000 | – | – | 16,835 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Nov 21, 2024 | Gift | −1,040 | – | – | 835 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Nov 19, 2024 | Option exercise | +2,500 | $5.14 | $12.85K | 3,305 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Nov 19, 2024 | Sale | −1,430 | $13.58 | $19.42K | 1,875 |
| Joseph P. Slattery Director | Aug 15, 2024 | Buy | +3,000 | $8.10 | $24.30K | 30,645 |
| Joseph P. Slattery Director | Aug 8, 2024 | Buy | +3,000 | $8.24 | $24.72K | 27,645 |
| Joseph P. Slattery Director | Aug 6, 2024 | Buy | +2,500 | $9.09 | $22.73K | 24,645 |
| Kevin Hykes PRES & CEO, Director | Aug 5, 2024 | Buy | +30,000 | $8.36 | $250.80K | 30,000 |
| Craig E. Palmer SVP, U.S. SALES | Mar 25, 2024 | Option exercise | +379 | $0.24 | $91 | 674 |
| Craig E. Palmer SVP, U.S. SALES | Mar 25, 2024 | Option exercise | +404 | $0.24 | $97 | 1,078 |
| Craig E. Palmer SVP, U.S. SALES | Mar 25, 2024 | Option exercise | +151 | $0.24 | $36 | 1,229 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +79 | $5.14 | $406 | 4,103,430 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +158 | $0.24 | $38 | 4,099,733 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +189 | $0.24 | $45 | 4,099,922 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +165 | $0.24 | $40 | 4,100,087 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +118 | $0.24 | $28 | 4,100,205 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CVRx's stock actually held short. Settlement fails (shares not delivered on time) peaked at 18,392 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ali Behbahani Officer | Nov 29, 2024 | 21,837 | $334.11K | Nov 29, 2024 | STOCK OPTION EXERCISE |
| Paul Verrastro Officer | Nov 19, 2024 | 1,430 | $19.42K | Nov 19, 2024 | Exercise of options under a registered plan |
| Ali Behbahani Officer | Nov 18, 2024 | 9 | $127 | Nov 18, 2024 | STOCK OPTION EXERCISE |
| New Enterprise Associates VIII, LP Affiliate | Nov 5, 2024 | 171,071 | $2.57M | Nov 5, 2024 | Private placement |
| NEA Enterprise Associates 8A, LP Affiliate | Nov 5, 2024 | 173,388 | $2.61M | Nov 5, 2024 | Private placement |
| Craig E. Palmer Officer | Jul 26, 2024 | 18,243 | $175.06K | Jul 26, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 25, 2024 | 11,880 | $113.91K | Jul 25, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 24, 2024 | 2,000 | $19.22K | Jul 24, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 23, 2024 | 2,000 | $20.14K | Jul 23, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 22, 2024 | 3,930 | $37.72K | Jul 22, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 16, 2024 | 7,152 | $70.48K | Jul 16, 2024 | STOCK OPTION EXERCISE |
| Paul Verrastro Officer | Feb 20, 2024 | 2,545 | $55.75K | Feb 20, 2024 | Exercise of options under a registered plan |
| Nehra John M Director | Aug 10, 2023 | 10,560 | $182.69K | Aug 10, 2023 | STOCK OPTION EXERCISE |
See a number that looks wrong?